All News

COVID vaccine vials

ACR Promotes New COVID-19 Vaccine Clinical Guidance for Rheumatic Patients

Jack Cush, MD

The American College of Rheumatology has published a draft guidance on the use of COVID-19 vaccination in rheumatic disease and musculoskeletal disease patients, based on the efforts of the North American Task force. The document provides guidance to rheumatology providers on the use of the COVID-19 vaccine and the associated management of RMD patients around the time of vaccination. Here is a summary of the recommendations.

Read Article
cardiac2.jpg (keep)

Comorbidity and Drugs Drive COVID-19 Severity and Survival in Rheumatic Disease

Jack Cush, MD

While comorbidities are associated with severe COVID-19 infection, it appears they also influence severity and survival in rheumatic disease (RMD), according to a a French cohort study,

Read Article
RheumNow Podcast square

RheumNow Podcast – Tofacitinib Safety Concerns (2.5.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and journal reports from the past week on RheumNow.com.

Read Article
patient.safety.jpg

JAK Inhibitor Misses Endpoint in Safety Study. Now What?

MedPage Today

Pfizer announced results Wednesday from its FDA-mandated postmarketing safety study of tofacitinib (Xeljanz), and they don't bode well for the drug and possibly others in its class.

Read Article
TB.EMimage.CDC_.jpg

Low Risk of TB with Secukinumab

Jack Cush, MD

JAMA Dermatology has reported on a longitudinal cohort study of 12,319 secukinumab (SEC) treated patients (psoriasis, psoriatic arthritis, or ankylosing spondylitis); no new cases of active tuberculosis (TB) and very few cases of latent tuberculosis infection (LTBI) were f

Read Article
2020 Year Review

2020 Rheumatology Year in Review

Jack Cush, MD

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related.

Read Article
Xeljanz4.jpg

Delays in Diagnosis of Axial Spondyloarthritis

Jack Cush, MD

The diagnosis of axial spondyloarthritis (and anklylosing spondylitis) (axSpA) is often delayed and usually not diagnosed by rheumatologists; a recent metanalysis shows that longer delays were attributable to lower education levels, younger age at onset and absence of extra-articular manifes

Read Article
Dr Eric Ruderman shows when pts are referred by MDs, vs self referred, they are more likely to have AxSpA (40 percent). Lectures from RWCS @RWCSmtg https://t.co/mRtMictVpq
Dr. John Cush RheumNow ( View Tweet)
Download available--Maintaining a Healthy Immune System https://t.co/wiWzZldnik https://t.co/ZL3r3dHPC2

Links:

Dr. John Cush RheumNow ( View Tweet)
British registry 801 axial SpA pts; 646 did not hve fibromyalgia at baseline & 46 (7%) developed FM over time. Of 115 axSpa w/ baseline FM, 77 (2/3) recovered. FM more likely with high Dz activity ((OR 1.27) & widespread pain (OR 1.14) https://t.co/4jOdaXIJuB https://t.co/ruOYj5HmMX

Links:

Dr. John Cush RheumNow ( View Tweet)
Sign up for RheumNow Live, March 20 and 21st. CME credits available. https://t.co/uwxOVh142F https://t.co/GqkCLBGl62

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/oGwmEXNaur https://t.co/qjwfaXXnXQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums: Got a Rheumatology question or case for RheumNow? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/wzNmOzH4VE https://t.co/6w8CAAUkO6

Links:

Dr. John Cush RheumNow ( View Tweet)
The EMA has Approved AbbVie’s Upadacitinib (Rinvoq) in the EU for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis. https://t.co/H5E8dazQx4

Links:

Dr. John Cush RheumNow ( View Tweet)

ACR Convergence 2020 Fireside Chats – Top presentations in nr-axSpA, AS, axial PsA Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at #ACR20? Listen to the experts as they present their views on the top abstracts. https://t.co/r5Cf4WS63s https://t.co/zN99Jo9bO0

Links:

Dr. John Cush RheumNow ( View Tweet)
Sign up to attend RheumNow Live--March 20 and 21. CME credits available https://t.co/vJlU0Z3Q3x https://t.co/Z0ectgFD2d

Links:

Dr. John Cush RheumNow ( View Tweet)
2020 Rheumatology Year in Review-- Read our top news items that rheumatologists should recollect and integrate into clinical standards for 2021 and beyond. https://t.co/QisCpdcLEa https://t.co/pZekUvcomE

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts. https://t.co/MD6lU5oIvy

Links:

Dr. John Cush RheumNow ( View Tweet)

Delays in Diagnosis of Axial Spondyloarthritis-Researchers found tht from 64 included studiesl, the mean diagnostic delay in axSpA patients was 6.7 years (95% CI 6.2, 7.2) with high levels of heterogeneity. https://t.co/cOC1R264aC https://t.co/5UC7aip7j0

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Late Breaking Abstracts available from the ACR "Spotlight" slide give away. 10 slides on COVID, Tyk2 in PsA, FAST febuxostat study, Tofa in AS and novel drugs for SLE and PSS https://t.co/DvcDyusCUR

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×